Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jindriska Lindsay
Response-Adapted Intensification With Cyclophosphamide, Bortezomib, and Dexamethasone Versus No Intensification in Patients With Newly Diagnosed Multiple Myeloma (Myeloma XI): A Multicentre, Open-Label, Randomised, Phase 3 Trial
The Lancet Haematology
Hematology
Related publications
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Pomalidomide Plus Low-Dose Dexamethasone Versus High-Dose Dexamethasone Alone for Patients With Relapsed and Refractory Multiple Myeloma (MM-003): A Randomised, Open-Label, Phase 3 Trial
The Lancet Oncology
Oncology
Phase I/Ii Study of Carfilzomib, Bendamustine, and Dexamethasone (CBD) in Patients With Newly Diagnosed Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Retreatment With Bendamustine-Bortezomib-Dexamethasone in a Patient With Relapsed/Refractory Multiple Myeloma
Case Reports in Hematology
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Phase 2 Trial of Ixazomib in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Blood Cancer Journal
Oncology
Hematology
Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma
Stem Cells International
Cell Biology
Molecular Biology
The MUK Five Protocol: A Phase II Randomised, Controlled, Parallel Group, Multi-Centre Trial of Carfilzomib, Cyclophosphamide and Dexamethasone (CCD) vs. Cyclophosphamide, Bortezomib (Velcade) and Dexamethasone (CVD) for First Relapse and Primary Refractory Multiple Myeloma
BMC Hematology
Hematology
Molecular Biology
Daratumumab in Untreated Newly Diagnosed Multiple Myeloma
Therapeutic Advances in Hematology
Hematology
